Michal Vieth to Speak at Protein Kinases Drug Design Oct 24-25, 2013 –San Diego

San Diego, CA, September 07, 2013 --(PR.com)-- Michal Vieth, Senior Research Advisor at Eli Lilly will give a presentation on “What Can We Learn from Kinase Profiling and in Silico Predictive Data?” at the 2nd Protein Kinases & Drug Design Conference to be held in San Diego, CA on October 24-25, 2013 by GTC.

General selectivity trends across kinase targets have implications to target selection, compound prioritization, understanding toxicity and patient tailoring. Michael Vieth will highlight the difficulty of drawing general conclusions from kinase selectivity data by highlighting differences in interpretation of data derived from different profiling panels. The general conclusions about how target space or general inhibitor class promiscuity are both profiling data and inhibitor set dependent using kinase set will be demonstrated. Could high quality in silico predictions in drug discovery eventually replace part or most of experimental testing? It is found that the overall level of agreement between predicted and experimental data to be comparable to that found between experimental results from different sources. However, for molecules which are either highly selective or potent, the concordance between different experimental sources is significantly higher than the concordance between experimental and predicted values.

Kinases, key drivers of malignant transformation and major contributors to a variety of other human pathologies, have emerged as some of the most exciting targets in drug discovery. However, with initial well documented success stories came realization that many hurdles lie in the path of successful development of new drugs, targeting kinase signaling. GTC’s 2nd Protein Kinases & Drug Design Conference will bring together speakers representing world leading academic centers and pharmaceutical companies to discuss how to overcome the many hurdles and answer exciting key questions.

This conference is part of our Protein Discovery Summit 2013, which includes three additional parallel conferences shown below:
Protein Kinases & Drug Design
Protein-Protein Interaction
Antibody & Protein Therapeutics
Protein Expression, Purification & Characterization

For more information, please visit www.gtcbio.com